1-8 of 8
A. Douglas Laird
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

Joanne L. Blum, A. Douglas Laird, Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri H. Roché, Kyung-Hun Lee, Annabel Goodwin, Ying Chen, Silvana Lanzalone, Jijumon Chelliserry, Akos Czibere, Julia F. Hopkins, Lee A. Albacker, Lida A. Mina
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1383–1390.
https://doi.org/10.1158/1078-0432.CCR-21-2080
Published: 01 April 2022
View article titled, Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <em>BRCA1/2</em>-Mutated Breast Cancer
Open the PDF for Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <em>BRCA1/2</em>-Mutated Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan M. O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, A. Douglas Laird, Anjali S. Advani
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2742–2754.
https://doi.org/10.1158/1078-0432.CCR-20-2399
Published: 15 May 2021
View article titled, Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22
Open the PDF for Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22 in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Vivian G. Oehler, Mark A. Schroeder, Jeffrey Lancet, James McCloskey, Hagop M. Kantarjian, Weidong Wendy Ma, M. Naveed Shaik, A. Douglas Laird, Mirjana Zeremski, Ashleigh O'Connell, Geoffrey Chan, Jorge E. Cortes
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (10): 2294–2303.
https://doi.org/10.1158/1078-0432.CCR-17-2824
Published: 14 May 2018
View article titled, Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Open the PDF for Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS in another window
Includes: Supplementary data
Journal Articles

CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back

Dirk B. Mendel, Julie M. Cherrington, A. Douglas Laird
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (11): 2415–2417.
https://doi.org/10.1158/1078-0432.CCR-14-2557
Published: 31 May 2015
View article titled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back
Open the PDF for <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back in another window
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W. Tolcher, José Baselga, Weiliang Shi, Coumaran Egile, Rodrigo Ruiz-Soto, A. Douglas Laird, Dale Miles, Patricia M. LoRusso
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (9): 2445–2456.
https://doi.org/10.1158/1078-0432.CCR-13-2403
Published: 30 April 2014
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Geoffrey I. Shapiro, Jordi Rodon, Cynthia Bedell, Eunice L. Kwak, Jose Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, A. Douglas Laird, Linh T. Nguyen, Yi Xu, Coumaran Egile, Gerald Edelman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (1): 233–245.
https://doi.org/10.1158/1078-0432.CCR-13-1777
Published: 05 January 2014
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647

Steven B. Gendreau, Richard Ventura, Paul Keast, A. Douglas Laird, F. Michael Yakes, Wentao Zhang, Frauke Bentzien, Belinda Cancilla, Jeffery Lutman, Felix Chu, Lisa Jackman, Yongchang Shi, Peiwen Yu, Jing Wang, Dana T. Aftab, Christopher T. Jaeger, Stephanie M. Meyer, Anushka De Costa, Kelly Engell, Jason Chen, Jean-Francois Martini, Alison H. Joly
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3713–3723.
https://doi.org/10.1158/1078-0432.CCR-06-2590
Published: 15 June 2007
View article titled, Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647
Open the PDF for Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647 in another window
Journal Articles

In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship

Dirk B. Mendel, A. Douglas Laird, Xiaohua Xin, Sharianne G. Louie, James G. Christensen, Guangmin Li, Randall E. Schreck, Tinya J. Abrams, Theresa J. Ngai, Leslie B. Lee, Lesley J. Murray, Jeremy Carver, Emily Chan, Katherine G. Moss, Joshua Ö. Haznedar, Juthamas Sukbuntherng, Robert A. Blake, Li Sun, Cho Tang, Todd Miller, Sheri Shirazian, Gerald McMahon, Julie M. Cherrington
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 327–337.
Published: 01 January 2003
View article titled, <em>In Vivo</em> Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: <subtitle>Determination of a Pharmacokinetic/Pharmacodynamic Relationship</subtitle>
Open the PDF for <em>In Vivo</em> Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: <subtitle>Determination of a Pharmacokinetic/Pharmacodynamic Relationship</subtitle> in another window